Issue 12, 2023

Bringing enzymes to the proximity party


Enzymes are used to treat a wide variety of human diseases, including lysosomal storage disorders, clotting disorders, and cancers. While enzyme therapeutics catalyze highly specific reactions, they often suffer from a lack of cellular or tissue selectivity. Targeting an enzyme to specific disease-driving cells and tissues can mitigate off-target toxicities and provide novel therapeutic avenues to treat otherwise intractable diseases. Targeted enzymes have been used to treat cancer, in which the enzyme is either carefully selected or engineered to reduce on-target off-tumor toxicity, or to treat lysosomal storage disorders in cell types that are not addressed by standard enzyme replacement therapies. In this review, we discuss the different targeted enzyme modalities and comment on the future of these approaches.

Graphical abstract: Bringing enzymes to the proximity party

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Review Article
05 Jun 2023
16 Sep 2023
First published
29 Sep 2023
This article is Open Access
Creative Commons BY license

RSC Chem. Biol., 2023,4, 986-1002

Bringing enzymes to the proximity party

G. S. Tender and C. R. Bertozzi, RSC Chem. Biol., 2023, 4, 986 DOI: 10.1039/D3CB00084B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity